HA
WST icon

Herold Advisors’s West Pharmaceutical WST Stock Holding History

Herold Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-807
Closed -$244K – 199
2022
Q2 		$244K Buy
807
+102
+14% +$33.2K 0.11% 171
2022
Q1 		$290K Buy
+705
New +$276K 0.1% 165
2021
Q4 		– Sell
-100
Closed -$42K – 652
2021
Q3 		$42K Buy
+100
New +$42.2K 0.02% 404

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Herold Advisors's WST Position: Q3 2022 in Review

Herold Advisors sold out of West Pharmaceutical (WST) in Q3 2022, closing a stake of 807 shares — an estimated $244K sold.

Herold Advisors first reported a position in WST in Q3 2021 and held it in 3 quarters. The position peaked at $290K in Q1 2022. 638 funds tracked by Wall St. Rank hold WST as of Q3 2022.

  • Herold Advisors reported no remaining West Pharmaceutical position as of Q3 2022 after selling out during the quarter.
  • Herold Advisors sold 807 West Pharmaceutical shares in Q3 2022, an estimated $244K.
  • Herold Advisors first reported a position in West Pharmaceutical in Q3 2021 and held it in 3 quarters.
  • Herold Advisors's West Pharmaceutical position peaked at $290K in Q1 2022.
  • 638 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2022.

Based on Herold Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.